This grand round has already taken place.
This program is designed to increase knowledge and understanding of endocrine pathology, diagnosis, and therapy that can be applied in practice.
Today's meeting will include recently published data regarding Thyroid Cancer diagnosis and management.
Dates and Times
Start: 10/19/2018 2:30 PM
End: 10/19/2018 3:00 PM
At the end of the presentation participants will be aware of recently published data relevant to the diagnosis and management of thyroid cancer.
There are two main overall objectives.
1. Understanding the difference in growth rate of malignant vs benign thyroid nodules.
- Looking at recent evidence in support of using growth for surveillance
- Clinically relevant (≥1 cm) malignant thyroid nodules grow more often and faster
- With every 2mm/yr increment of growth, see a progressive increase in RR of malignancy
- Nodule growth rate may be an important consideration in nodules that have not undergone cytologic assessment or for observed thyroid cancers
-During f/u reduction in nodule size by 2mm or more per year should suggest a very low risk of a malignancy
- Data suggest that thyroid nodule growth should be reintroduced as an important variable in the evaluation and follow up of thyroid nodules
2. Using thyroglobulin measurement after lobectomy as a marker for recurrence of disease.
- Looking at recent evidence in support and against using TG in this regard. Also will look at data for risk stratification of these patients.
-Data validate newly proposed response to therapy assessment in patients with DTC treated with lobectomy or TT without RAI as an effective tool to: modify initial risk estimates of recurrent/persistent SED and Better tailor followup and future therapeutic approaches
-Observed that biochemical incomplete response to therapy due to increasing nonstimulated Tg or increasing TgAb was able to correctly identify recurrent/persistent SED in patients treated with lobectomy and that all these patients were rended with on SED with additional therapy
-Trend of nonstimulated Tg was the strongest predictor of recurrent/persistent SED and important than the absolute nonstimulated Tg levels
However the other article shows opposite evidence:
-Serum Tg levels in the lobectomy patients increased gradually without definite evidence of disease recurrence
-Suggests a compensatory increase of remnant thyroid tissue after lobectomy that may contribute to the increases seen in the serum Tg levels
-No significant difference in serum Tg level changes between patients with or without recurrent disease
-Periodic measurements of serum Tg levels were not useful for predicting recurrent disease in these patients
Understand the prognostic value of BRAFV600E and TERT mutations for Papillary thyroid cancer
-Discuss low versus high dose RAI in the treatment of low risk thyroid cancer following total thyroidectomy
101 Nicolls Road
UH Level 2 Pathology Conference Room
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.